Combination treatment for early breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of targeted therapies and hormone therapy for early-stage breast cancer that is HER2-positive and hormone receptor-positive. The goal is to see if this treatment can help shrink the tumor before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 to 75.
- Your breast cancer must be HER2-positive and hormone receptor-positive (ER-positive and/or PR-positive).
- Your cancer must be early-stage (not spread to distant organs).
- You must be able to perform daily activities with minimal difficulty (ECOG score 0-1).
- You must have adequate organ function and a healthy heart.
- You must not have had any prior cancer treatment for this breast cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This trial tests a combination of targeted therapies (pertuzumab and trastuzumab) and hormone therapy (palbociclib and exemestane) given before surgery for triple-positive breast cancer. The goal is to see if this package effectively shrinks the tumor and improves outcomes.
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial tests a combination of two targeted therapies given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see if this approach is safe and effective for early-stage breast cancer.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) before surgery for women with early-stage HER2-positive breast cancer. The goal is to shrink the tumor and improve treatment outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.